AR040334A1 - Amidas de aminoacidos ciclicos como inhibidores de la pde 4 - Google Patents

Amidas de aminoacidos ciclicos como inhibidores de la pde 4

Info

Publication number
AR040334A1
AR040334A1 ARP030102241A ARP030102241A AR040334A1 AR 040334 A1 AR040334 A1 AR 040334A1 AR P030102241 A ARP030102241 A AR P030102241A AR P030102241 A ARP030102241 A AR P030102241A AR 040334 A1 AR040334 A1 AR 040334A1
Authority
AR
Argentina
Prior art keywords
alkyl
mono
straight
branched chain
polysubstituted
Prior art date
Application number
ARP030102241A
Other languages
English (en)
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of AR040334A1 publication Critical patent/AR040334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Amidas sustituidas de aminoácidos cíclicos caracterizadas porque tienen de la fórmula general (1), donde n puede ser 1 ó 2, X puede ser -NH2, -N=C(R3)-R4 (configuración E o Z, o syn o anti), -NH-CH(R3)-R4, -N(R3)-CH(R3)-R4, -NH-CH2-R4 o -NH-(C=O)-R4, R1 y R4 pueden ser iguales o diferentes y pueden ser carbociclos mono policíclicos saturados o mono o poliinsaturados con 3 a 14 miembros de anillo, heterociclos mono o policíclicos saturados o mono o poliinsaturados con 5 a 15 miembros de anillo y 1-6 heteroátomos, con preferencia, N, O y/o S, donde los carbociclos o los heterociclos pueden estar, a su vez, opcionalmente mono o polisustituidos por -F, -Cl, -Br, -I, -OH, -NO2, -NH-CO-alquilo C1-6, de cadena lineal o ramificada, -COOH, -COO-alquilo C1-6, de cadena lineal o ramificada, -alquilo C1-6, de cadena lineal o ramificada, -alquiloxi C1-6, de cadena lineal o ramificada, -cicloalquilo C3-7, -cicloalquiloxi C3-7, N(R3)2, -CON(R3)2, o -SO2N(R3)2, y donde cada radical alquilo o alquiloxi a su vez puede estar mono o polisustituido por halógeno, -OH, -cicloalquilo C3-7 y/o -cicloalquiloxi C3-7 y cada radical cicloalquilo o cicloalquiloxi puede estar a su vez mono o polisustituido por halógeno, -OH, -alquilo C1-6 y/o -alquiloxi C1-6, donde opcionalmente dos sustituyentes adyacentes a R1 o R4 pueden estar puenteados entre sí; R2 en cada caso, en forma independiente entre sí, puede ser H o alquilo C1-6, de cadena lineal o ramificada, o bencilo, donde cada radical alquilo puede estar mono o polisustituido por halógeno, -OH, -cicloalquilo C3-7 y/o -cicloalquiloxi C3-7 y cada radical bencilo puede estar mono o polisustituido por -F, -Cl, -Br, -I, -OH, -NO2, -NH-CO-alquilo C1-6, de cadena lineal o ramificada, -COOH, -COO-alquilo C1-6, de cadena lineal o ramificada, -alquilo C1-6, de cadena lineal o ramificada, -alquiloxi C1-6, de cadena lineal o ramificada, -cicloalquilo C3-7, -cicloalquiloxi C3-7, N(R3)2 y/o -CON(R3)2, y donde cada radical alquilo o alquiloxi puede estar a su vez mono o polisustituido por halógeno, -OH, -cicloalquilo C3-7 y/o -cicloalquiloxi C3-7 y cada radical cicloalquilo o cicloalquiloxi puede estar a su vez mono o polisustituido por halógeno, -OH, -alquilo C1-6 y/o -alquiloxi C1-6, R1-N-R2 puede ser además un sistema cíclico heterocíclico con contenido de N, donde el sistema cíclico heterocíclico puede estar opcionalmente mono o polisustituido por -F, -Cl, -Br, -I, -OH, -NO2, -NH-CO-alquilo C1-6, de cadena lineal o ramificada, -COOH, -COO-alquilo C1-6, de cadena lineal o ramificada, -alquilo C1-6, de cadena lineal o ramificada, -alquiloxi C1-6, de cadena lineal o ramificada, -cicloalquilo C3-7, -cicloalquiloxi C3-7, N(R3)2 y/o -CON(R3)2, y donde cada radical alquilo o alquiloxi puede estar a su vez mono o polisustituido por halógeno, -OH, -cicloalquilo C3-7 y/o -cicloalquiloxi C3-7 y cada radical cicloalquilo o cicloalquiloxi puede estar a su vez mono o polisustituido por halógeno, -OH, -alquilo C1-6 y/o -alquiloxi C1-6; R3 puede ser en cada caso, en forma independiente, H o alquilo C1-6, de cadena lineal o ramificada, donde cada radical alquilo puede estar, a su vez, opcionalmente mono o polisustituidos por halógeno, -OH, -cicloalquilo C3-7 y/o -cicloalquiloxi C3-7, así como sus sales, con la condición de que el compuesto (1) no sea (3-isobutiloxi-4-metoxifenil)amida de ácido 1-(3,4-dimetoxibencilamino)-piperidin-2-carboxílico o m-cloro-N-[2-[9,9-dimetil-10-acridanil)carbonil-1-pirrolidinil]benzamida.
ARP030102241A 2002-06-24 2003-06-23 Amidas de aminoacidos ciclicos como inhibidores de la pde 4 AR040334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10228132A DE10228132A1 (de) 2002-06-24 2002-06-24 Amide cyclischer Aminosäuren als PDE 4 Inhibitoren

Publications (1)

Publication Number Publication Date
AR040334A1 true AR040334A1 (es) 2005-03-30

Family

ID=29761345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102241A AR040334A1 (es) 2002-06-24 2003-06-23 Amidas de aminoacidos ciclicos como inhibidores de la pde 4

Country Status (5)

Country Link
AR (1) AR040334A1 (es)
AU (1) AU2003245979A1 (es)
DE (1) DE10228132A1 (es)
TW (1) TW200410936A (es)
WO (1) WO2004000806A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US8026365B2 (en) 2007-05-25 2011-09-27 Hoffman-La Roche Inc. 4,4-disubstituted piperidine derivatives
EP3778577B1 (en) * 2018-05-09 2023-08-30 Lg Chem, Ltd. Novel compound exhibiting enteropeptidase inhibitory activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6603820A (es) * 1965-03-24 1966-09-26
IT1245712B (it) * 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
AU8059598A (en) * 1998-06-11 1999-12-30 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors

Also Published As

Publication number Publication date
DE10228132A1 (de) 2004-01-22
WO2004000806A1 (de) 2003-12-31
AU2003245979A1 (en) 2004-01-06
TW200410936A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR042053A1 (es) Hidroxiindoles nuevos, su uso como inhibidores de la fosfodiestrasa - 4, y procesos para su preparacion
DK1856045T3 (da) 1-eddikesyreindolderviater med PGD2-antagonisteffekt
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2'.
PE20040804A1 (es) DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR038379A1 (es) Esteres de acidos fluoreno-carboxilicos, procedimientos para su preparacion asi como su utilizacion en calidad de medicamentos
AR033620A1 (es) Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BRPI0414792A (pt) derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose
ECSP078003A (es) Inhibidores de aspartil proteasas
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
ES2192864T3 (es) Inhibidores de p38.
AR047085A1 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
CO5601013A2 (es) Compuestos que modulan la actividad de ppar
ECSP099446A (es) Piperidinas sustituidas que contienen una unidad heteroarilamida o heteroarilfenilo
CO6160330A2 (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
CO5640129A2 (es) Agonistas del receptor activado por proliferador de peroxisoma
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
AR040334A1 (es) Amidas de aminoacidos ciclicos como inhibidores de la pde 4
AR017256A1 (es) Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
PE20050312A1 (es) Compuestos de peptidilo como inhibidores de catepsina s
DOP2006000133A (es) Derivados de 4,5 diarilpiroxol, su preparación y su aplicación en terapeútica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal